Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

BackgroundExtended‐duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clini...

Full description

Bibliographic Details
Main Authors: C. Michael Gibson, Serge Korjian, Gerald Chi, Yazan Daaboul, Purva Jain, Douglas Arbetter, Samuel Z. Goldhaber, Russel Hull, Adrian F. Hernandez, Renato D. Lopes, Alex Gold, Alexander T. Cohen, Robert A. Harrington
Format: Article
Language:English
Published: Wiley 2017-07-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
death
intracranial hemorrhage
ischemic stroke
myocardial infarction
pulmonary embolism
venous thromboembolism
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.117.006015

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.117.006015

Similar Items